Various hormonal and monoaminergic systems play determinant roles in the regulation of several cytochromes P450 (P450s) in the liver. Growth hormone (GH), prolactin, and insulin are involved in P450 regulation, and their release is under dopaminergic control. This study focused on the role of D₂-dopaminergic systems in the regulation of the major drug-metabolizing P450s, i.e., CYP3A, CYP2C, and CYP2D. Blockade of D₂-dopaminergic receptors with either sulpiride (SULP) or 4-(4-chlorophenyl)-1-(1H-indol-3-ylmethyl)piperidin-4-ol (L-741,626) markedly down-regulated CYP3A1/2, CYP2C11, and CYP2D1 expression in rat liver. This suppressive effect appeared to be mediated by the insulin/phosphatidylinositol 3-kinase/Akt/FOXO1 signaling pathway. Furthermore, inactivation of the GH/STAT5b signaling pathway appeared to play a role in D₂-dopaminergic receptor-mediated down-regulating effects on these P450s. SULP suppressed plasma GH levels, with subsequently reduced activation of STAT5b, which is the major GH pulse-activated transcription factor and has up-regulating effects on various P450s in hepatic tissue. Levels of prolactin, which exerts down-regulating control on P450s, were increased by SULP, which may contribute to SULP-mediated effects. Finally, it appears that SULP-induced inactivation of the cAMP/protein kinase A/cAMP-response element-binding protein signaling pathway, which is a critical regulator of pregnane X receptor and hepatocyte nuclear factor 1α, and inactivation of the c-Jun N-terminal kinase contribute to SULP-induced down-regulation of the aforementioned P450s. Taken together, the present data provide evidence that drugs acting as D₂-dopaminergic receptor antagonists might interfere with several major signaling pathways involved in the regulation of CYP3A, CYP2C, and CYP2D, which are critical enzymes in drug metabolism, thus affecting the effectiveness of the majority of prescribed drugs and the toxicity and carcinogenic potency of a plethora of toxicants and carcinogens.

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.112.078709DOI Listing

Publication Analysis

Top Keywords

cyp3a cyp2c
12
cyp2c cyp2d
12
signaling pathway
12
role d₂-dopaminergic
8
effects p450s
8
p450s
6
d₂-dopaminergic
5
d₂-dopaminergic receptor-linked
4
receptor-linked pathways
4
pathways critical
4

Similar Publications

Article Synopsis
  • This study identifies the formation of covalent protein adducts from drug metabolism as significant risk factors for adverse drug reactions and cytochrome P450 enzyme inactivation.
  • It introduces a novel liquid chromatography with tandem mass spectrometry (LC-MS/MS) approach to detect low abundance drug-protein adducts in human liver microsomes, using raloxifene as a model.
  • The findings reveal adducts in multiple proteins, including CYP enzymes, and suggest that some adducts may be harmless, providing a framework for better understanding the human adductome related to drug exposure.
View Article and Find Full Text PDF
Article Synopsis
  • A study investigated the effects of diphenhydramine (DPH), an antihistamine found in global water sources, on marbled crayfish (Procambarus virginalis) over a 96-hour exposure period, focusing on CYP metabolism and oxidative stress.* -
  • The crayfish showed CYP activity through specific substrates, indicating functions similar to mammalian detoxification, but higher DPH concentrations led to a slight reduction in transformation activities.* -
  • Antioxidant enzyme responses were significantly altered in the gills and hepatopancreas due to DPH exposure, with gills identified as the key tissue for assessing DPH toxicity in these aquatic organisms.*
View Article and Find Full Text PDF
Article Synopsis
  • The Association for Molecular Pathology's Pharmacogenomics Working Group aims to establish key attributes and a standard set of genetic variants for clinical pharmacogenetic testing.
  • The document outlines two tiers of recommended genetic variants, which will guide clinical laboratories in creating pharmacogenomics assays.
  • Focused on dihydropyrimidine dehydrogenase (DPYD) testing, the recommendations encourage standardization while serving as a flexible reference rather than strict rules.
View Article and Find Full Text PDF

Pregnane X receptor activation induces liver enlargement and regeneration and simultaneously promotes the metabolic activity of CYP3A1/2 and CYP2C6/11 in rats.

Basic Clin Pharmacol Toxicol

August 2024

NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hong Kong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.

Human pregnane X receptor (PXR) is critical for regulating the expression of key drug-metabolizing enzymes such as CYP3A and CYP2C. Our recent study revealed that treatment with rodent-specific PXR agonist pregnenolone-16α-carbonitrile (PCN) significantly induced hepatomegaly and promoted liver regeneration after two-thirds partial hepatectomy (PHx) in mice. However, it remains unclear whether PXR activation induces hepatomegaly and liver regeneration and simultaneously promotes metabolic function of the liver.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!